Sai Parenteral's Ltd.
SAIPARENTERALMainboard
Ask IPO
Overview
Sai Parenterals Limited is a diversified pharmaceutical company specializing in Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets. Its product portfolio covers a wide range of therapeutic areas, including cardiovascular, anti-diabetic, and antibiotics, offered in various dosage forms like injectables, tablets, and capsules. The company operates five manufacturing facilities in India and has recently expanded its global footprint by acquiring a majority stake in Australia-based Noumed Pharmaceuticals, enhancing its presence in regulated markets.
Opening Date
Mar 24, 2026
Closing Date
Mar 27, 2026
Listing Date
Apr 02, 2026
IPO Type
Mainboard
IPO Status
Closed
Issue Size
408.79 Cr
Fresh Issue
285 Cr
Offer for Sale
123.79 Cr
Price Band
₹372 - ₹392
Lot Size
38
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
The main objectives of the issue are to fund several key growth and financial initiatives.
- •
Funding capital expenditure for the capacity expansion and upgradation of existing manufacturing facilities, including Units I, II, III, and IV, to enhance production capabilities and meet international regulatory standards.
- •
Financing the establishment of a new, dedicated Research and Development (R&D) center to strengthen formulation development, support regulatory filings, and accelerate product innovation.
- •
Repayment or prepayment of certain outstanding borrowings availed by the company to deleverage the balance sheet and reduce finance costs.
- •
Augmenting working capital requirements to support the growing scale of operations and fund the gap between receivables and payables.
- •
Repayment of a bridge loan and term loan that were availed for the strategic investment in its wholly-owned subsidiary, Sai Parenterals Pte Limited (Singapore), which was used for the acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
Key Performance Indicator
P/E Ratio
72.19
EPS
5.43
ROE
16.82%
ROCE
28.92%
RONW
15.09%
Debt to Equity Ratio
—
PAT Margin
8.88%
EBITDA Margin
24.18%
P/B
10.89
SWOT Analysis
Strengths
- •
Diversified business model with a strong presence in Branded Generic Formulations and CDMO services.
- •
Strategically located and internationally accredited manufacturing facilities with multi-dosage capabilities.
- •
Track record of value-accretive acquisitions that have expanded manufacturing capacity and market reach.
- •
Experienced promoters and senior management team with extensive domain knowledge in the pharmaceutical industry.
Weaknesses
- •
High concentration of manufacturing facilities in Telangana and Andhra Pradesh, exposing the company to regional risks.
- •
Significant revenue dependence on a limited number of key customers.
- •
Lack of long-term contracts with most raw material suppliers, leading to potential supply and price volatility.
- •
Periodic inspections by regulatory authorities can lead to potential operational disruptions or regulatory actions.
Opportunities
- •
Leverage the upcoming patent cliff, representing an estimated $130 billion opportunity in developed markets.
- •
Capitalize on the 'China Plus One' strategy as global firms seek alternative manufacturing hubs.
- •
Expand presence in high-growth emerging and semi-regulated markets across Africa, Southeast Asia, and Latin America.
- •
Grow the high-margin global injectable formulations market, which is projected to be the fastest-growing dosage form.
Threats
- •
Intense competition from both large multinational corporations and domestic pharmaceutical companies.
- •
Stringent and evolving regulations in the pharmaceutical industry can lead to compliance challenges and delays.
- •
Economic slowdown or political instability in India could adversely affect domestic business operations and growth.
- •
Fluctuations in foreign exchange rates could impact the profitability of international business operations.
Subscription Rate
Frequently Asked Questions about Sai Parenteral's Ltd.
Sai Parenterals Limited is a diversified pharmaceutical company specializing in Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets. Its product portfolio covers a wide range of therapeutic areas, including cardiovascular, anti-diabetic, and antibiotics, offered in various dosage forms like injectables, tablets, and capsules. The company operates five manufacturing facilities in India and has recently expanded its global footprint by acquiring a majority stake in Australia-based Noumed Pharmaceuticals, enhancing its presence in regulated markets.
The Sai Parenteral's Ltd. IPO is scheduled to open for subscription on Mar 24, 2026 and close on Mar 27, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Sai Parenteral's Ltd. IPO is ₹372 to ₹392. Investors can place bids within this range once the issue opens.
The minimum lot size for the Sai Parenteral's Ltd. IPO is 38 shares. The minimum investment amount ₹14,896.
The total issue size of the Sai Parenteral's Ltd. IPO is approximately ₹408.79. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Sai Parenteral's Ltd. IPO has been subscribed 0.42 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Sai Parenteral's Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Sai Parenteral's Ltd. are expected to list on stock exchanges on Apr 02, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Sai Parenteral's Ltd. IPO are proposed to be used for The main objectives of the issue are to fund several key growth and financial initiatives., Funding capital expenditure for the capacity expansion and upgradation of existing manufacturing facilities, including Units I, II, III, and IV, to enhance production capabilities and meet international regulatory standards., Financing the establishment of a new, dedicated Research and Development (R&D) center to strengthen formulation development, support regulatory filings, and accelerate product innovation., Repayment or prepayment of certain outstanding borrowings availed by the company to deleverage the balance sheet and reduce finance costs., Augmenting working capital requirements to support the growing scale of operations and fund the gap between receivables and payables., Repayment of a bridge loan and term loan that were availed for the strategic investment in its wholly-owned subsidiary, Sai Parenterals Pte Limited (Singapore), which was used for the acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
Before applying for the Sai Parenteral's Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
